首页> 美国卫生研究院文献>Nanomaterials >Preconcentration and Detection of Gefitinib Anti-Cancer Drug Traces from Water and Human Plasma Samples by Means of Magnetic Nanoparticles
【2h】

Preconcentration and Detection of Gefitinib Anti-Cancer Drug Traces from Water and Human Plasma Samples by Means of Magnetic Nanoparticles

机译:通过磁性纳米颗粒从水和人体血浆样品中预浓缩和检测吉非替尼抗癌药物的痕迹

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Along of widespread application of anti-cancer drug Gefitinib (GEF), it appears in human body fluids as well as clinical wastewater. Consequently, a reliable and easy-to-adapt detection technique is of essential importance to quantify the drug in different media. The extraction and quantitative detection of anti-cancer drug Gefinitib (GEF) is demonstrated based on a straightforward and efficient magnetic nanoparticle-assisted preconcentration route from water and human plasma samples. Iron oxide magnetic nanoparticles (Fe O ) have been prepared with an average particle size of 15 nm and utilized as extractible adsorbents for the magnetic solid-phase extraction (MSPE) of GEF in aqueous media. The method is based on MSPE and preconcentration of GEF followed by High-Performance Liquid Chromatography-Ultraviolet Detection (HPLC-UV). The yield of GEF extraction under the optimum MSPE conditions were 94% and 87% for water and plasma samples, respectively. The chromatographic separation was carried out isocratically at 25 °C on a Phenomenex C8 reversed phase column (150 mm × 4.6 mm, with 5 µm particle size). The proposed method was linear over concentration ranges of 15.0–300.0 and 80.0–600.0 ng/mL for water and plasma samples with limits of detection of 4.6 and 25.0 ng/mL in a respective order. Relative standard deviations (%RSD) for intra-day and inter-day were 0.75 and 0.94 for water samples and 1.26 and 1.70 for plasma samples, respectively. Using the magnetic nanoparticles (MNPs) as loaded drug-extractors made the detection of the anti-cancer drug environmentally friendly and simple and has great potential to be used for different drug-containing systems.
机译:随着抗癌药物吉非替尼(GEF)的广泛应用,它出现在人体液体以及临床废水中。因此,可靠且易于适应的检测技术对于量化不同培养基中的药物至关重要。基于从水和人血浆样品中直接而有效的磁性纳米粒子辅助的预富集路线,证明了抗癌药吉非替尼(GEF)的提取和定量检测。已经制备了平均粒径为15 nm的氧化铁磁性纳米颗粒(Fe O),并用作可萃取的吸附剂,用于GEF在水性介质中的磁性固相萃取(MSPE)。该方法基于MSPE和GEF的预浓缩,然后进行高效液相色谱-紫外检测(HPLC-UV)。在最佳MSPE条件下,水和血浆样品的GEF提取率分别为94%和87%。色谱分离是在Phenomenex C8反相色谱柱(150 mm×4.6 mm,粒径为5 µm)上于25°C等度进行的。对于水和血浆样品,所提出的方法在15.0–300.0和80.0–600.0 ng / mL的浓度范围内是线性的,检出限分别为4.6和25.0 ng / mL。水样品的日内和日间相对标准偏差(%RSD)分别为0.75和0.94,血浆样品为1.26和1.70。使用磁性纳米颗粒(MNP)作为负载的药物提取器,使得抗癌药物的检测既环保又简单,并且具有用于不同含药系统的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号